Pharmacological Inhibition of Cav2.2 Channels by Recombinant Phα1β Toxin (CTK01512‐2)
Basic & Clinical Pharmacology & Toxicology · 2026-08 · 139 (2)
DOI: 10.1111/bcpt.70268 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, online erschienen am 01.07.2026. Verfasst von Natália Virtude Carobin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculdade de Saúde Santa Casa BH, Belo Horizonte, Minas Gerais, Brazil. Hauptthemen laut MEDLINE: Calcium Channels, N-Type, Spider Venoms, Neuralgia, Analgesics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa do Estado de Minas Gerais.
Abstract (Originalsprache)
Phα1β is a peptide toxin originally isolated from the venom of the Brazilian spider Phoneutria nigriventer , known for its potent analgesic effects in preclinical models of acute and chronic pain. However, clinical translation has been limited by production constraints. A recombinant analogue, CTK01512‐2, was developed and has demonstrated antinociceptive efficacy comparable to the native toxin in diverse experimental models. In this study, we examined the effects of CTK01512‐2 on N‐type voltage‐gated calcium channels (Cav2.2) expressed in transiently transfected HEK‐293 cells and confirmed its antinociceptive action in a mouse model of neuropathic pain. CTK01512‐2 induced a partial (~50%) and reversible inhibition of Cav2.2‐mediated calcium currents, with a calculated half‐maximal inhibitory concentration (IC 50 ) of 3.94 nM. In contrast to ω‐conotoxin MVIIA, a clinically approved irreversible Cav2.2 blocker, CTK01512‐2 allowed current recovery after washout, indicating reversible binding. Notably, the toxin did not significantly alter the voltage dependence or kinetics of channel activation. These findings identify CTK01512‐2 as a selective and reversible Cav2.2 channel modulator, underscoring its therapeutic potential as a novel analgesic agent for chronic pain management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculdade de Saúde Santa Casa BH, Belo Horizonte, Minas Gerais, Brazil.
- Psychological & Brain Science, Indiana University, Bloomington, Indiana, USA.
- Departamento de Fisiologia, Universidade Federal de Sergipe, São Cristóvão, Sergipe, Brazil.
ORCID-Profile: Christopher Kushmerick
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais
Zitieren
APA
Carobin, N. V., Moraes, T. R., Ferreira, L. A., Kushmerick, C., Gomez, M. V., & Junior, C. J. C. (2026). Pharmacological Inhibition of Cav2.2 Channels by Recombinant Phα1β Toxin (CTK01512‐2). Basic & Clinical Pharmacology & Toxicology, 139(2). https://doi.org/10.1111/bcpt.70268
Vancouver
Carobin NV, Moraes TR, Ferreira LA, Kushmerick C, Gomez MV, Junior CJC. Pharmacological Inhibition of Cav2.2 Channels by Recombinant Phα1β Toxin (CTK01512‐2). Basic & Clinical Pharmacology & Toxicology. 2026;139(2). doi:10.1111/bcpt.70268
BibTeX
@article{Carobin2026,
author = {Carobin, Natália Virtude and Moraes, Thamyris Reis and Ferreira, Luana Assis and Kushmerick, Christopher and Gomez, Marcus Vinícius and Junior, Célio José Castro},
title = {Pharmacological Inhibition of Cav2.2 Channels by Recombinant Phα1β Toxin (CTK01512‐2)},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2026},
volume = {139},
number = {2},
doi = {10.1111/bcpt.70268}
}
EUVIMED